2021, Volume 7, Issue 7
Engineering >> 2021, Volume 7, Issue 7 doi: 10.1016/j.eng.2021.03.014
COVID-19 Vaccine Allocation: Modeling Health Outcomes and Equity Implications of Alternative Strategies
Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
Next Previous
Abstract
Given the scarcity of safe and effective COVID-19 vaccines, a chief policy question is how to allocate them among different sociodemographic groups. This paper evaluates COVID-19 vaccine prioritization strategies proposed to date, focusing on their stated goals; the mechanisms through which the selected allocations affect the course and burden of the pandemic; and the main epidemiological, economic, logistical, and political issues that arise when setting the prioritization strategy. The paper uses a simple, agestratified susceptible–exposed–infectious–recovered model applied to the United States to quantitatively assess the performance of alternative prioritization strategies with respect to avoided deaths, avoided infections, and life-years gained. We demonstrate that prioritizing essential workers is a viable strategy for reducing the number of cases and years of life lost, while the largest reduction in deaths is achieved by prioritizing older adults in most scenarios, even if the vaccine is effective at blocking viral transmission. Uncertainty regarding this property and potential delays in dose delivery reinforce the call for prioritizing older adults. Additionally, we investigate the strength of the equity motive that would support an allocation strategy attaching absolute priority to essential workers for a vaccine that reduces infectionfatality risk.
Keywords
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
References
[ 1 ] coronavirus.jhu.edu [Internet]. Baltimore: Johns Hopkins University & Medicine; 2020 [cited 2020 Dec 14]. Available from: https://coronavirus.jhu. edu/map.html. link1
[ 2 ] International Monetary Fund. World Economic Outlook, October 2020: a long and difficult ascent [Internet]. Washington, DC: International Monetary Fund 2020 [cited 2020 Dec 13]. Available from: https://www.imf.org/en/ Publications/WEO/Issues/2020/09/30/world-economic-outlook-october-2020. link1
[ 3 ] Bloom DE, Cadarette D, Ferranna M, Hyer RN, Tortorice DL. How new models of vaccine development for COVID-19 have helped address an epic public health crisis. Health Aff 2021;40(3):410–8. link1
[ 4 ] Zimmer C, Corum J, Wee SL. Coronavirus vaccine tracker [Internet]. New York: The New York Times Company; 2020 [cited 2021 Feb 24]. Available from: https://www.nytimes.com/interactive/2020/science/coronavirusvaccine-tracker.html. link1
[ 5 ] Institute of Medicine. The 2009 H1N1 influenza vaccination campaign: summary of a workshop series [Internet]. Washington, DC: The National Academy Press; 2010. Available from: http://www.ncbi.nlm.nih.gov/books/ NBK54185/. link1
[ 6 ] Skrip LA, Galvani AP. Next steps for Ebola vaccination: deployment in nonepidemic, high-risk settings. PLoS Negl Trop Dis 2016;10(8):e0004802. link1
[ 7 ] Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr 2021;175(2):143–56. link1
[ 8 ] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20(6):669–77. link1
[ 9 ] Mahase E. COVID-19: what have we learnt about the new variant in the UK? BMJ 2020;371:m4944. link1
[10] Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science 2009;325(5948):1705–8. link1
[11] Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Respir Med 2020;8(6):547–8. link1
[12] Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med 2020;382(26):2534–43. link1
[13] Brown C, Ravallion M. Inequality and the coronavirus: socioeconomic covariates of behavioral responses and viral outcomes across US counties. NBER working paper. 2020 Jul. No.: w27549.
[14] Goodnough A, Hoffman J. The elderly vs. essential workers: who should get the coronavirus vaccine first [Internet]. New York: The New York Times Company; 2020 [cited 2020 Dec 6]. Available from: https://www.nytimes.com/2020/12/ 05/health/covid-vaccine-first.html. link1
[15] Persad G, Peek ME, Emanuel EJ. Fairly prioritizing groups for access to COVID19 vaccines. JAMA 2020;324(16):1601–2. link1
[16] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Sci Adv 2021;7(6):eabf1374.
[17] Rodríguez J, Patón M, Acuña JM. Prioritisation of population groups with the most interactions for COVID-19 vaccination can substantially reduce total fatalities. 2020. medRxiv:2020.10.12.20211094v3.
[18] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Modelinformed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021;371(6532):916–21. link1
[19] Gallagher ME, Sieben AJ, Nelson KN, Kraay ANM, Orenstein WA, Lopman B, et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat Med 2021;27(1):4–5. link1
[20] Chen X, Li M, Simchi-Levi D, Zhao T. Allocation of COVID-19 vaccines under limited supply. 2020. medRxiv:2020.08.23.20179820.
[21] Forslid R, Herzing M. Whom to vaccinate first—some important trade-offs. CEPR discussion paper. 2021 Feb. No.: DP15800.
[22] Chen JZ, Hoops S, Marathe A, Mortveit H, Lewis B, Venkatramanan S, et al. Prioritizing allocation of COVID-19 vaccines based on social contacts increases vaccination effectiveness. 2021. medRxiv:2021.02.04.21251012.
[23] Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. 2020. medRxiv:2020.09.22.20199174.
[24] Biggerstaff M. Modeling strategies for the initial allocation of SARS-CoV-2 vaccines [Internet]. 2020 [cited 2020 Oct 30]. Available from: https://www. cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/COVIDBiggerstaff-508.pdf. link1
[25] Babus A, Das S, Lee SM. The optimal allocation of COVID-19 vaccines. 2020. medRxiv:2020.07.22.20160143.
[26] Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. 2020. medRxiv: 2020.09.22.20194183.
[27] Jentsch P, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes. 2020. medRxiv:2020.09.25. 20201889.
[28] Rahmandad H. Behavioral responses to risk promote vaccinating high-contact individuals first. 2021. medRxiv:2021.02.05.21251215.
[29] Vellodi N, Weiss J. Optimal vaccine policies: spillovers and incentives. Covid Econ 2021;65:1–46. link1
[30] Castonguay FM, Blackwood JC, Howerton E, Shea K, Sims C, Sanchirico JN. Spatial allocation of scarce vaccine and antivirals for COVID-19. 2021. medRxiv:2020.12.18.20248439.
[31] National Academy of Sciences Engineering and Medicine. Framework for equitable allocation of COVID-19 vaccine. Washington, DC: The National Academy Press; 2020. link1
[32] Toner E, Barnill A, Krubiner C, Bernstein J. Interim framework for COVID-19 vaccine allocation and distribution in the United States [Internet]. Baltimore: The Johns Hopkins Center for Health Security; 2020. Available from: https:// www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/ 200819-vaccine-allocation.pdf. link1
[33] Centers for Disease Control and Prevention. How CDC is making COVID19 vaccine recommendations [Internet]. Washington, DC: Centers for Disease Control and Prevention; 2020 [cited 2021 Jan 4]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations. html. link1
[34] Joint Committee on Vaccination and Immunisation. Priority groups for Coronavirus (COVID-19) vaccination: advice from the JCVI, 2 December 2020 [Internet]. London: Joint Committee on Vaccination and Immunisation; 2020 [cited 2020 Dec 2]. Available from: https://www.gov.uk/government/ publications/priority-groups-for-coronavirus-covid-19-vaccination-advicefrom-the-jcvi-2-december-2020/priority-groups-for-coronavirus-covid-19- vaccination-advice-from-the-jcvi-2-december-2020. link1
[35] World Health Organization (WHO). Fair allocation mechanisms for COVID-19 vaccines through the COVAX facility [Internet]. Geneva: World Health Organization; 2020 [cited 2020 Sep 9]. Available from: https://www. who.int/publications/m/item/fair-allocation-mechanism-for-covid-19- vaccines- through-the-covax-facility. link1
[36] WHO Strategic Advisory Group of Experts. Values framework for the allocation and prioritization of COVID-19 vaccination [Internet]. Geneva: WHO; 2020 [cited 2020 Sep 14]. Available from: https://apps.who.int/iris/bitstream/ handle/10665/334299/WHO-2019-nCoV-SAGE_Framework-Allocation_and_ prioritization-2020.1-eng.pdf. link1
[37] Advisory Committee on Immunization Practices (ACIP). Phased allocation of COVID-19 vaccines [Internet]. Washington, DC: Centers for Disease Control and Prevention; 2020 [cited 2020 Dec 15]. Available from: https://www. cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/COVID-02- Dooling-508.pdf. link1
[38] Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The advisory committee on immunization practices’ updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69(5152):1657–60. link1
[39] Peiris M, Leung GM. What can we expect from first-generation COVID-19 vaccines? Lancet 2020;396(10261):1467–9. link1
[40] www.cisa.gov [Internet]. Washington, DC: Cybersecurity & Infrastructure Security Agency; 2020 [cited 2020 Dec 14]. Available from: https:// www.cisa.gov/publication/guidance-essential-critical-infrastructure-workforce. link1
[41] Emanuel EJ, Wertheimer A. Who should get influenza vaccine when not all can? Science 2006;312(5775):854–5. link1
[42] Blau FD, Koebe J, Meyerhofer PA. Who are the essential and frontiline workers? [Internet]. NBER Working Paper n. 27791: 2021. Available from: https://www. nber.org/system/files/working_papers/w27791/w27791.pdf. link1
[43] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. In press.
[44] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403–16. link1
[45] Rasmussen AL. Does the vaccine stop transmission? [Internet]. New York: The New York Times Company; 2021 [cited 2021 Feb 23]. Available from: https:// www.nytimes.com/2021/02/23/opinion/covid-vaccines-transmission.html. link1
[46] Bauch CT. Estimating the COVID-19 R number: a bargain with the devil? Lancet Infect Dis 2021;21(2):151–3. link1
[47] Schmidt H, Weintraub R, Williams MA, Buttenheim A, Sadecki E, Wu H, et al. Equitable allocation of COVID-19 vaccines: an analysis of the initial allocation plans of CDC’s jurisdictions with implications for disparate impact monitoring [Internet]. Rochester: SSRN; 2021. Available from: https://ssrn.com/ abstract=3740041. link1
[48] NPR. Early data shows striking racial disparities in who’s getting the COVID-19 vaccine [Internet]. NPR; 2021 Jan 28 [cited 2021 Jan 28]. Available from: https://www.npr.org/transcripts/961703505. link1
[49] Zhang C, Bushey C. Racial inequality plagues US vaccine rollout [Internet]. The Financial Times Ltd.; 2021 [cited 2021 Feb 20]. Available from: https://www. ft.com/content/7b0db882-a369-4e32-a86a-eb7fda2a0da0. link1
[50] Roberts M, Andreasen V, Lloyd A, Pellis L. Nine challenges for deterministic epidemic models. Epidemics 2015;10:49–53. link1
[51] Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588(7837):315–20. link1
[52] Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA 2020;323(24):2466–7. link1
[53] Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al.; CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019— United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69(13):382–6.
[54] Wu X, Nethery RC, Sabath MB, Braun D, Dominici F. Air pollution and COVID19 mortality in the United States: strengths and limitations of an ecological regression analysis. Sci Adv 2020;6(45):eabd4049.
[55] See how the vaccine rollout is going in your state [Internet]. New York: The New York Times Company; 2021 [cited 2021 Feb 23]. Available from: https:// www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html. link1
[56] Public Health England. COVID-19: The Green Book, Chapter 14a [Internet]. London: Public Health England; 2020 [cited 2021 Feb 20]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/948757/Greenbook_chapter_14a_v4.pdf. link1
京公网安备 11010502051620号
